ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Towa Pharmaceutical Co., Ltd.

Business Summary

Towa Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. Its products include neurological and anti-allergic drugs, cardiovascular and respiratory drugs, gastrointestinal drugs, antibiotics and chemotherapeutic drugs, vitamins; hormone drugs, and other metabolic drugs. The company was founded in June 1951 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue110,384M1,015.25M
Gross Profit50,646M465.81M
Operating income16,151M148.54M
Income before tax20,709M190.47M
Net income14,503M133.39M
EBITDA24,436M224.74M
Diluted EPS272.612.50
Dividends Per Share440.40
Total Assets228,138M2,113.26M
Total liabilities123,487M1,143.87M
Total equity104,649M969.37M
Operating cash flow19,164M176.25M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 82,115M 84,949M 93,430M 105,104M 110,384M
Gross Profit 41,854M 39,047M 43,051M 48,399M 50,646M
Operating income 11,134M 7,143M 11,644M 16,283M 16,151M
Income before tax 9,903M 7,237M 9,833M 18,886M 20,709M
Net income 7,684M 5,576M 6,495M 13,475M 14,503M
EBITDA 27,998M 15,123M 19,817M 24,623M 24,436M
Diluted EPS 145.43 104.74 122.02 253.31 272.61
Dividends Per Share 31.66 31.66 31.66 35.83 44
Total Assets 156,851M 165,247M 177,655M 189,158M 228,138M
Total liabilities 86,246M 90,299M 97,733M 97,386M 123,487M
Total equity 70,605M 74,945M 79,920M 91,771M 104,649M
Operating cash flow 3,732M 10,195M 19,230M 19,002M 19,164M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 683.81M 784.47M 842.98M 947.78M 1,015.25M
Gross Profit 348.53M 360.58M 388.43M 436.44M 465.81M
Operating income 92.71M 65.96M 105.05M 146.83M 148.54M
Income before tax 82.46M 66.83M 88.71M 170.30M 190.47M
Net income 63.98M 51.49M 58.60M 121.51M 133.39M
EBITDA 233.15M 139.65M 178.80M 222.03M 224.74M
Diluted EPS 1.21 0.96 1.10 2.28 2.50
Dividends Per Share 0.26 0.29 0.28 0.32 0.40
Total Assets 1,395.53M 1,482.96M 1,670.47M 1,708.97M 2,113.26M
Total liabilities 767.34M 810.36M 918.97M 879.84M 1,143.87M
Total equity 628.18M 672.57M 751.48M 829.11M 969.37M
Operating cash flow 31.07M 94.14M 173.50M 171.35M 176.25M

Valuation Measures

Mar 2020
PER7.69
ROA6.95%
ROE14.76%
Operating margin14.63%
Profit margin13.13%

Key executives

  • President & Representative Director: Itsuro Yoshida
  • Executive Officer, GM-Research & Development: Takeshi Sugiura
  • Executive Officer & Deputy General Manager-Sales: Masaji Morikawa
  • Executive Officer & Manager-Accounting: Shinya Kida
  • Director, GM-Administration & Manager-IR: Masao Tanaka

Shareholders

  • YOSHIDA FAMILY /TOWA PHARMACEUTICAL/ (39.0%)
  • Towa Pharmaceutical Co., Ltd. (4.4%)
  • YOSHIDA ITSURO (2.8%)
  • Towa Pharmaceutical Business Association (2.7%)
  • Asset Management One Co., Ltd. (2.1%)
  • Nomura Asset Management Co., Ltd. (1.8%)
  • Towa Pharmaceutical Employee Stock Ownership Plan (1.5%)
  • Brown Capital Management LLC (1.4%)
  • The Vanguard Group, Inc. (1.3%)
  • Goldman Sachs Asset Management LP (1.3%)

Contact Details

Related Companies

  • Towa Pharmaceutical Restricted Stock Compensation Plan
  • Pensa Investments SL
  • Daichi Kasei KK
  • J-Dolph Co., Ltd.
  • Towa Pharmaceutical Business Association
  • Towa Pharmaceutical Employee Stock Ownership Plan

Competitors

    Last Updated on 27 Oct, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Try 1 month for $0.99

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends October 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to Nikkei Asia has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more